November 15, 2021
TesoRx Subsidiary LIPAC Oncology to Present Two-Year Data for Phase 1/2a Study of Lipax at the 22nd Annual Meeting of the Society of Urologic Oncology More...
October 7, 2021
TesoRx Subsidiary LIPAC Oncology Secures Broad Patent Protection for Proliposomal Paclitaxel Compositions Formulated for Delivery to the Bladder and Ureter for the Treatment of Solid Tumor Carcinomas More…
September 21, 2021
TesoRx Subsidiary LIPAC Oncology To Present at Upcoming Investor Conferences More…
June 9, 2021
TesoRx Subsidiary LIPAC Oncology Announces Two-Year Recurrence Free Survival Data for Phase 1/2a Study of LiPax in Patients With Non-Muscle Invasive Bladder Cancer More…
May 13, 2021
TesoRx Subsidiary LIPAC Oncology Names Daniel K. Spiegelman as Independent Board Advisor More…
May 6, 2021
TesoRx Subsidiary LIPAC Oncology Announces Appointment of Josh Hamermesh to the Board of Directors More…
April 29, 2021
TesoRx Subsidiary LIPAC Oncology Announces Successful Type B Meeting with the U.S. FDA for the Study of LiPax for Non-Muscle Invasive Bladder Cancer More…
December 10, 2020
TesoRx Subsidiary LIPAC Oncology Announces Major Partnering Milestone Achieved in its License Agreement with Huons Co., Ltd. More…
September 22, 2020
TesoRx Announces Successful Completion of Confirmative Study of Oral Testosterone Candidate TSX-049 More…
September 8, 2020
TesoRx Subsidiary LIPAC Oncology Announces Completion of Phase 2A Clinical Trial of LiPax in Patients with Non-Muscle Invasive Bladder Cancer More…
May 18, 2020
TesoRx Subsidiary LIPAC Oncology Announces Presentation of Data from Phase 1/2a Study of LiPax in Patients with Highly Recurrent Bladder Cancer More…
January 12, 2020
TesoRx Subsidiary LIPAC Oncology Announces Acceptance of an Abstract for Presentation at the American Urological Association Annual Meeting in May 2020 More…
November 26, 2019
TesoRx Provides Update on Clinical Development Program for Oral Testosterone Candidate TSX-049 More...
October 25, 2019
TesoRx Subsidiary LIPAC Oncology Announces Successful Completion of Phase 1 Bladder Cancer Clinical Study and Initiation of Phase 2A Study More...
September 16, 2019
TesoRx Subsidiary LIPAC Oncology and Huons Co. Announce Exclusive Licensing Agreement for TBC-1002 in Korea More...
December 1, 2017
TesoRx Pharma And ASKA Pharmaceutical Expand Territory And Scope Of Partnering Agreement For TesoRx's Oral Testosterone Product - ASKA makes Equity Investment into TesoRx. More...
November 30, 2017
TesoRx Announces Commencement of Enrollment of a Clinical Trial Evaluating Novel Oral Testosterone Replacement Therapy in Patients with Hypogonadism. More...
April 27, 2017
ASKA and TesoRx Announce TSX-011 (Oral Testosterone) Proceeding to Human Studies Following Successful PK Study Results. More...
January 9, 2017
TesoRx Announces Creation of LIPAC Oncology and Advancement of Oncology Pipeline. More...
ASKA and TesoRx Announce Partnership to Develop Oral Testosterone for the Japanese Market. More...
June 8, 2016
FDA grants orphan designation for TesoRx's unmodified Testosterone treatment for Constitutional Delay in Growth in Puberty (CDGP) for boys. More...
April 3, 2015
Official Opening of TesoRx Centre of Excellence at Western University. More...
October 20, 2014
TesoRx and Aspen Group Conclude Investment and Licensing Agreement. More...
August 5, 2014
TesoRx Closes $10M in Funding, Secures Key Patent and Hires Renowned Urologist as Chief Medical Officer. More...
May 16, 2014
TesoRx Announces Participation at the American Urological Association (AUA) 2014 Conference. More...
August 28, 2013
TesoRx and CoreRx Announce Joint Venture to Manufacture First-in-Class Oral Testosterone Drug. More...
December 31, 2010
TesoRx closes Series A funding round. More...
July 30, 2010
TesoRx licenses Testosterone Replacement Therapy technology. More...
April 30, 2010
Well-known pharma personality forms TesoRx. More...